Modified Yeast RNA Antiviral Agent Broad-Spectrum Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral drugs often target specific viruses and are ineffective against multiple viral infections due to rapid development of drug resistance, and there is a need for agents that can inhibit viral penetration and release mechanisms across various viral families.
Innovation Solution
Development of an RNA-based therapeutic agent synthesized from yeast-derived ribonucleic acid, which activates the innate immune system and has multiple antiviral actions against different viruses, including influenza, hepatitis C, and herpes viruses, by inhibiting neuraminidase and hemagglutinin activities.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current antiviral drugs target specific viruses, then they can effectively treat that specific virus, but they are ineffective against multiple viral infections due to rapid development of drug resistance
Solution Approach 1:
The patent applies universality by developing RNA-based agents that can simultaneously target multiple viruses through different mechanisms. The composition includes various RNAs (antisense RNAs, ribozymes, aptamers) that collectively provide broad-spectrum antiviral activity against influenza, hepatitis C, herpes, and other viruses, making a single composition capable of treating multiple viral infections rather than requiring separate drugs for each virus
Solution Approach 2:
The patent applies segmentation by dividing the antiviral mechanism into multiple distinct RNA components, each targeting specific viral processes. The composition contains antisense RNAs that bind to viral transcripts, ribozymes that catalyze RNA cleavage, and aptamers that inhibit viral proteins. This segmented approach allows each RNA component to address specific viral resistance mechanisms while collectively providing broad coverage
2Duration of action of stationary object
If synthetic ribozymes are used to achieve long-term inhibition of viral transcripts, then sustained effect is required, but efficient delivery into appropriate cells in vivo and maintaining high-level inhibition is difficult to achieve
Solution Approach 1:
The patent applies merging by combining multiple types of therapeutic RNAs (antisense RNAs, ribozymes, and aptamers) into a single composition that can be administered together. This combined approach addresses delivery challenges by utilizing multiple delivery pathways and mechanisms simultaneously, with different RNA types having complementary pharmacokinetic properties that ensure sustained presence in target cells
Solution Approach 2:
The patent applies intermediary by using modified nucleotides and chemical modifications on the RNA molecules to protect them from degradation and facilitate cellular uptake. These modifications act as intermediaries that enhance stability, improve delivery efficiency, and prolong the duration of action of the therapeutic RNAs in vivo
3Reliability
If chemically synthesized oligonucleotides are used to bind target proteins with high affinity, then specific binding is achieved, but they are subject to nuclease-mediated degradation by serum nucleases with half-life not exceeding 2 minutes
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the oligonucleotides through nucleotide modifications. These modifications change physical and chemical parameters such as resistance to nucleases, cellular uptake efficiency, and serum stability, thereby extending half-life from minutes to hours while preserving binding affinity and specificity for target viral proteins
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The RNA-based agent demonstrates potent antiviral activity with a high chemotherapeutic index, effectively inhibiting viral replication and reducing symptoms in various viral infections without side effects, making it suitable for complex viral disease management.
Implementation Method 1
activates the innate immune system
Implementation Method 2
inhibiting neuraminidase and hemagglutinin activities
Implementation Method 3
inhibiting neuraminidase and hemagglutinin activities
Data Source
Figure 1~4
Figure 5~8
Figure 9~12
AI summary
A method for obtaining a new antiviral compound with multiple action against many viruses, comprising modified highly purified yeast RNA, a pharmaceutical composition comprising such RNA, and a method for the treatment and prevention of viral disease comprising administering to a patient a composition comprising an amount effective to ameliorate the symptoms of viral disease of ribonucleic acid. The exogenous modified yeast RNA has a pronounced multiple anti-virus action in a wide range of concentrations. The modified yeast RNA is capable of inhibiting the reproduction of viruses from Orthomyxoviridae, Paramyxovirus, Hepatitis, Herpesviridae families, enterovirus and adenovirus. Also, the modified yeast RNA is capable of inhibiting the reproduction of influenza viruses, hepatitis C virus, genital herpes, human immunodeficiency virus and Coxsackie B virus.